Nebula Research & Development’s Xenon Pharmaceuticals XENE Stock Holding History

Nebula Research & Development’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-60,223	Closed	-$1.88M	–	888
2025 Q2	$1.88M	Buy	60,223 +13,662	+29%	+$446K	0.16%	205
2025 Q1	$1.56M	Buy	46,561 +26,201	+129%	+$995K	0.14%	232
2024 Q4	$798K	Sell	20,360 -3,905	-16%	-$161K	0.09%	372
2024 Q3	$955K	Sell	24,265 -5,931	-20%	-$239K	0.11%	303
2024 Q2	$1.18M	Buy	+30,196	New	+$1.21M	0.19%	170
2024 Q1	–	Sell	-7,281	Closed	-$335K	–	1026
2023 Q4	$335K	Buy	+7,281	New	+$257K	0.1%	402

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Nebula Research & Development's XENE Position: Q3 2025 in Review

Nebula Research & Development sold out of Xenon Pharmaceuticals (XENE) in Q3 2025, closing a stake of 60,223 shares — an estimated $1.88M sold.

Nebula Research & Development first reported a position in XENE in Q4 2023 and held it in 6 quarters. The position peaked at $1.88M in Q2 2025. 219 funds tracked by Wall St. Rank hold XENE as of Q3 2025.

Nebula Research & Development reported no remaining Xenon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Nebula Research & Development sold 60,223 Xenon Pharmaceuticals shares in Q3 2025, an estimated $1.88M.
Nebula Research & Development first reported a position in Xenon Pharmaceuticals in Q4 2023 and held it in 6 quarters.
Nebula Research & Development's Xenon Pharmaceuticals position peaked at $1.88M in Q2 2025.
219 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.